ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are in clinical trials: VAL201 (Phase I/II) – a peptide for advanced prostate cancer and potential to treat other hormoneinduced indications; and VAL401 (Phase II) – a novel reformulation of risperidone, in trials for lung cancer. Both drugs are targeted at multi-billion dollar markets that are inadequately served by current drugs. The aim is to progress the clinical data and exit via a collaboration or commercial out-licensing to a larger partner.
31 May 2017
Developing novel cancer therapies
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Developing novel cancer therapies
ValiRx PLC (VAL:LON) | 3.6 0 0.0% | Mkt Cap: 4.70m
- Published:
31 May 2017 -
Author:
Martin Hall -
Pages:
40
ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are in clinical trials: VAL201 (Phase I/II) – a peptide for advanced prostate cancer and potential to treat other hormoneinduced indications; and VAL401 (Phase II) – a novel reformulation of risperidone, in trials for lung cancer. Both drugs are targeted at multi-billion dollar markets that are inadequately served by current drugs. The aim is to progress the clinical data and exit via a collaboration or commercial out-licensing to a larger partner.